Beyond anti-VEGF: Dual-targeting antiangiogenic and antiproliferative therapy

American Journal of Translational Research

Volumn 5, Issue 4, 2013, Pages 393-403

  Chen, Chun Te ^a   Hung, Mien Chie ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

Author keywords

5 fluorouracil; Antiangiogenesis; Bevacizumab; Chemotherapy; Endothelial cell targeting

Indexed keywords

BEVACIZUMAB; CYTOSINE DEAMINASE; ENDOSTATIN; FLUCYTOSINE; FLUOROURACIL; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ENDOSTATIN; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIPROLIFERATIVE ACTIVITY; ARTERIAL THROMBOEMBOLISM; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); COLORECTAL LIVER METASTASIS; DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; ENZYME PRODRUG THERAPY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; WOUND HEALING IMPAIRMENT;

EID: 84878325052     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
3. Kerbel R and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
4. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
5. Fong GH, Rossant J, Gertsenstein M and Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
6. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML and Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
7. Dvorak HF, Brown LF, Detmar M and Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
8. Terman BI and Stoletov KV. VEGF and Tumor Angiogenesis. Einstein Quart. J Biol and Med 2001; 18: 59-66.
9. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
10. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004; 22: 1198.
11. Cohen MH, Gootenberg J, Keegan P and Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12: 713-718.
12. Cohen MH, Shen YL, Keegan P and Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131-1138.
13. Summers J, Cohen MH, Keegan P and Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010; 15: 104-111.
14. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
15. Ivy SP, Wick JY and Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6: 569-579.
16. Eto M and Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol 2006; 11: 209-213.
17. Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007; 7: 617-626.
18. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R and Pazdur R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107-113.
19. Morgan G, Ward R and Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) 2004; 16: 549-560.
20. Orditura M, Quaglia F, Morgillo F, Martinelli E, Lieto E, De Rosa G, Comunale D, Diadema MR, Ciardiello F, Catalano G and De Vita F. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncol Rep 2004; 12: 549-556.
21. Hasani A and Leighl N. Classification and toxicities of vascular disrupting agents. Clin Lung Cancer 2011; 12: 18-25.
22. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29: 10-14.
23. Kramer I and Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32: 1-14.
24. Force T, Krause DS and Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344.
25. Chen HX and Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-477.
26. Schmidt C. Why do tumors become resistant to antiangiogenesis drugs? J Natl Cancer Inst 2009; 101: 1530-1532.
27. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D and Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-475.
28. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21: 21-26.
29. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J and Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-5101.
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
31. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
32. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
33. Loges S, Mazzone M, Hohensinner P and Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
34. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
35. Azam F, Mehta S and Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010; 46: 1323-1332.
36. Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009; 115: 2306-2312.
37. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C and Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
38. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM and De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
39. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O and Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
40. Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 2003; 88: 201-211.
41. Tuma RS. Dosing study seen as victory for clinical trials, mathematical models. J Natl Cancer Inst 2003; 95: 254-255.
42. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J and Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369-3372.
43. Brown JM and Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
44. Ma J and Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008; 7: 3670-3684.
45. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
46. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R and Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
47. Teicher BA. Antiangiogenic agents and targets: A perspective. Biochem Pharmacol 2010; 81: 6-12.
48. Moreno Garcia V, Basu B, Molife LR and Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012; 18: 3750-3761.
49. Chung AS, Lee J and Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-514.
50. Boehm T, Folkman J, Browder T and O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
51. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
52. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003; 100: 4766-4771.
53. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L and Huber PE. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
54. Zhang DW, Li HL, Yao Q, Yang WL, Wang HL, Zhai DX and Zhou ZH. The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma. J Int Med Res 2010; 38: 111-126.
55. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
56. Nyberg P, Xie L and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967-3979.
57. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP and Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555-3561.
58. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK and Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792-3803.
59. Jiang LP, Zou C, Yuan X, Luo W, Wen Y and Chen Y. N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem 2009; 54: 113-120.
60. Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, Zhu Y, Zhou Q, Hou M, Guan Z, Li W, Zhuang W, Wang D, Liang H, Qin F, Lu H, Liu X, Sun H, Luo S, Yang R, Tu Y, Wang X, Song S, Zhou J, You L and Yao C. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi 2005; 8: 283-290.
61. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001; 33: 357-369.
62. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J and Javaherian K. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008; 14: 1487-1493.
63. Tysome JR, Wang P, Alusi G, Briat A, Gangeswaran R, Wang J, Bhakta V, Fodor I, Lemoine NR and Wang Y. Lister Vaccine Strain of Vaccinia Virus Armed with the Endostatin-Angiostatin Fusion Gene: An Oncolytic Virus Superior to dl1520 (ONYX-015) for Human Head and Neck Cancer. Hum Gene Ther 2011 Sep; 22: 1101-8.
64. Belur LR, Podetz-Pedersen KM, Sorenson BS, Hsu AH, Parker JB, Carlson CS, Saltzman DA, Ramakrishnan S and McIvor RS. Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer 2011; 10: 14.
65. Jing Y, Lu H, Wu K, Subramanian IV and Ramakrishnan S. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins. Int J Cancer 2011 Aug 1; 129: 751-61.
66. Frei E 3rd, Teicher BA, Holden SA, Cathcart KN and Wang YY. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417-6423.
67. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF and Kerr DJ. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547-1554.
68. Ramnaraine M, Pan W, Goblirsch M, Lynch C, Lewis V, Orchard P, Mantyh P and Clohisy DR. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003; 63: 6847-6854.
69. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R and Mehtali M. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
70. Diasio RB and Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237.
71. Springer CJ and Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000; 105: 1161-1167.
72. Xu G and McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001; 7: 3314-3324.
73. Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, Xie X, Hung JY, Wei Y, Hortobagyi GN and Hung MC. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006; 66: 378-384.
74. Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN and Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-Cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther 2011; 10: 1327-1336.
75. Yeh ET and Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-2247.
76. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA and Shima DT. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999; 5: 495-502.
77. Verheul HM and Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485.
78. Avraamides CJ, Garmy-Susini B and Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8: 604-617.
79. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-36.
80. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.